MFN News Items | Nanologica

Nanologica Publishes Annual Report for 2020

5 May, 2021

Nanologica hereby announces that the annual report for 2020 has been published. The report is available on the company’s website www.nanologica.com. For further information, please contact: Johanna Johansson, IR Nanologica Ph: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com About Nanologica AB (publ) Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface characteristics of silica particles. Through the two

Kallelse till årsstämma i Nanologica AB (publ)

28 April, 2021

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 27 maj 2021. Mot bakgrund av risken för spridning av Covid-19 och myndigheternas föreskrifter/råd om undvikande av sammankomster har styrelsen beslutat att bolagsstämman ska genomföras utan fysisk närvaro genom att aktieägare utövar sin rösträtt endast genom poströstning. Någon fysisk sammankomst kommer således inte att hållas. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i

Nanologica Interim Report Jan-Mar 2021

23 April, 2021

Summary of the period FINANCIAL OVERVIEW · Net revenue increased by 54 percent to TSEK 5,622 (3,654) · The operating profit and loss for the period was TSEK -6,768 (-6,032) · Profit and loss after tax for the period was TSEK -7,845 (-6,705) · Earnings per share for the period was SEK -0.28 (-0.40) · Cash and cash equivalents at the end of the period amounted to TSEK 57,069 (1,273) SIGNIFICANT EVENTS DURING THE FIRST

Nanologica Announces Date Change for Annual Report

21 April, 2021

Nanologica AB (publ) has changed the previously disclosed publication date of April 23, 2021 for the company’s annual report 2020 to May 5, 2021. Financial calendar 2021 Interim report January-March 2021 April 23, 2021 Annual Report 2020 May 5, 2021 Interim report January-June 2021

Nanologica’s Nomination Committee Proposes Thomas Eldered as New Board Member of Nanologica AB

13 April, 2021

Thomas Eldered, who recently left his position as CEO of Recipharm and who is Nanologica’s largest shareholder, is proposed as new member of the Board of Directors to be elected at the Annual General Meeting on May 27. Thomas Eldered holds a M.Sc. in Industrial and Management Engineering from Linköping Institute of Technology and is the co-founder of Recipharm AB, where he was also the CEO from 2008–2021. Before that, Thomas was the Vice President

Nanologicas valberedning föreslår nyval av Thomas Eldered som styrelseledamot i Nanologica AB

13 April, 2021

Thomas Eldered, som nyligen lämnade sin post som vd för Recipharm och som är Nanologicas största aktieägare, föreslås av valberedningen i Nanologica att väljas in som ledamot i styrelsen vid årsstämman den 27 maj. Thomas Eldered är civilingenjör i industriell ekonomi från Linköpings tekniska högskola och ärmedgrundare av Recipharm AB, där han också var verksam som vd mellan 2008–2021. Före det varThomas Vice President för Recip AB 1995–2007. Valberedningen föreslår i övrigt omval av Gisela

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.